Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares IssuedShares RepurchasedShort-Term Debt repayments
Ratios

Ani Pharmaceuticals (ANIP) Depreciation & Amortization (IS) (2016 - 2025)

Historic Depreciation & Amortization (IS) for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $22.6 million.

  • Ani Pharmaceuticals' Depreciation & Amortization (IS) rose 4371.35% to $22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.4 million, marking a year-over-year increase of 5151.93%. This contributed to the annual value of $67.7 million for FY2024, which is 1327.96% up from last year.
  • Ani Pharmaceuticals' Depreciation & Amortization (IS) amounted to $22.6 million in Q3 2025, which was up 4371.35% from $23.3 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Depreciation & Amortization (IS) high stood at $23.3 million for Q2 2025, and its period low was $10.9 million during Q1 2021.
  • For the 5-year period, Ani Pharmaceuticals' Depreciation & Amortization (IS) averaged around $15.8 million, with its median value being $14.7 million (2023).
  • Its Depreciation & Amortization (IS) has fluctuated over the past 5 years, first crashed by 254.85% in 2021, then surged by 5840.65% in 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Depreciation & Amortization (IS) (Quarter) stood at $13.7 million in 2021, then rose by 5.85% to $14.5 million in 2022, then rose by 4.9% to $15.2 million in 2023, then skyrocketed by 48.74% to $22.6 million in 2024, then increased by 0.14% to $22.6 million in 2025.
  • Its last three reported values are $22.6 million in Q3 2025, $23.3 million for Q2 2025, and $22.9 million during Q1 2025.